Skip to content
value.today

Oyster Point Pharma, Inc.

🇺🇸 San Francisco, California, USAPharmaceuticalsFounded 2015
Total raised
$114 M
2 rounds on record
Latest round
$85 M
Feb 2019
First round on record
Oct 2017
Today
Acquired
Acquired by Viatris Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Oyster Point Pharma, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Oyster Point Pharma, IncViatris Inc.2023—$427 M—Annual report

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Oyster Point Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2019$85 MNo. 2$50 to $250 million

Oyster Point Pharma, Inc.: Raise no. 2, Feb 2019

Investors in this round

7 investors had bought by the notice of Feb 27, 2019: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 30 investors are named for Oyster Point Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $93 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey A. Nau · Executive Officer, Director
  • Mark A. Murray · Executive Officer, Director
  • Ali J Behbahani · Director
  • Benjamin A. Tsai · Director
  • Clare A. Ozawa · Director
  • D. Michael Ackermann · Director
  • William J Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Nau, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 27, 2019. Read the notice at the SEC.

equitySEC
Oct 2017$29 MNo. 1$10 to $50 million

Oyster Point Pharma, Inc.: Raise no. 1, Oct 2017

Investors in this round

8 investors had bought by the notice of Oct 25, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 30 investors are named for Oyster Point Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$29 M of $43 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey A. Nau · Executive Officer, Director
  • Mark A. Murray · Executive Officer, Director
  • Ali J Behbahani · Director
  • D. Michael Ackermann · Director
  • William J Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Nau, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 25, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Oyster Point Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2019

That is all the official record says: Oyster Point Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

30 named in official filings. Open an investor to see everything it has backed.

Investors in Oyster Point Pharma, Inc.
InvestorKindAmountRoundRoleSource
Falcon Vision LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
InvOpps GP IV, L.L.C.Othernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
InvOpps IV, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
InvOpps IV US, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
KKR Associates HCSG L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR & Co. L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Fund Holdings GP LtdFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Fund Holdings L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Group Holdings Corp.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Hcsg GP LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Healthcare Strategic Growth Fund L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KKR Management LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Kleiner Perkins Caufield & Byers XIV, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KPCB XIV Associates, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KPCB XIV Founders Fund, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Mark Anthony MurrayPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2019)SEC Form 3
Nea 14 GP, LTDCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
NEA Partners 14, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
New Enterprise Associates 14, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Oyster Point Pharma I, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Side Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Vantage I GP-GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Vantage I GP, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Vantage I, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Venture Capital IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Venture Capital VI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Ventures IV, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Ventures VI GP-GP, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Versant Ventures VI GP, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Vida Ventures, LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Oyster Point Pharma, Inc.
NameRoleNamed in
Jeffrey A. NauExecutive officerFeb 2019
Mark A. MurrayExecutive officerFeb 2019
Ali J BehbahaniDirectorFeb 2019
Benjamin A. TsaiDirectorFeb 2019
Clare A. OzawaDirectorFeb 2019
D. Michael AckermannDirectorFeb 2019
Jeffrey A. NauDirectorFeb 2019
Mark A. MurrayDirectorFeb 2019
William J LinkDirectorFeb 2019

Acquired (Jan 1, 2023). Acquired by Viatris Inc..